Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study

Area of Science:

• Oncology
• Urologic Oncology
• Sarcoma Research

Background:

• Adult prostatic sarcoma (PS) is a rare malignancy.
• Current treatment paradigms primarily rely on surgery, with limited established roles for other therapies.
• This study presents findings from the largest multicentric cohort of PS patients to date.

Purpose of the Study:

• To evaluate treatment outcomes in a large cohort of adult prostatic sarcoma patients.
• To investigate the impact of various therapeutic modalities, including surgery and radiotherapy, on patient survival and local control.
• To identify prognostic factors influencing outcomes in prostatic sarcoma.

Main Methods:

• A multicentric study involving 61 adult PS patients from 16 institutions.
• Patients received treatments including curative surgery (prostatectomy, cystoprostatectomy) with lymphadenectomy, curative radiotherapy (radical, neoadjuvant, postoperative), and chemotherapy.
• Data on patient demographics, treatment details, and follow-up outcomes were collected and analyzed.

Main Results:

• The 5-year overall survival and local control rates were 53% and 47%, respectively.
• Curative radiotherapy was associated with improved 5-year local control (55% vs. 31%, P=0.02) and overall survival (59% vs. 46%, P=0.1).
• Surgically treated patients with locally advanced tumors (cT3-4) who received radiotherapy demonstrated significantly improved 5-year local control (68% vs. 33%, P=0.004) and overall survival (65% vs. 21%, P<0.001).

Conclusions:

• Adult prostatic sarcoma carries a generally poor prognosis.
• Locally advanced tumors are associated with inferior local control and overall survival rates.
• Curative radiotherapy should be considered a vital component of the multidisciplinary management of prostatic sarcoma.